- Home
- ABUS vs CAC Comparison
ABUS vs CAC Comparison
Compare ABUS & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABUS | CAC |
|---|---|---|
| Founded | 2005 | 1875 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.5M | 680.5M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | ABUS | CAC |
|---|---|---|
| Price | $4.05 | $45.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.00 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 1.6M | 83.4K |
| Earning Date | 11-13-2025 | 01-27-2026 |
| Dividend Yield | N/A | ★ 3.71% |
| EPS Growth | N/A | ★ 9.13 |
| EPS | N/A | ★ 3.49 |
| Revenue | $14,606,000.00 | ★ $215,172,000.00 |
| Revenue This Year | $125.30 | $44.50 |
| Revenue Next Year | N/A | $7.82 |
| P/E Ratio | ★ N/A | $12.97 |
| Revenue Growth | ★ 116.64 | 27.50 |
| 52 Week Low | $2.71 | $34.53 |
| 52 Week High | $5.10 | $46.80 |
Technical Indicators
Market Signals| Indicator | ABUS | CAC |
|---|---|---|
| Relative Strength Index (RSI) | 35.17 | 58.39 |
| Support Level | $4.39 | $42.21 |
| Resistance Level | $4.86 | $45.77 |
| Average True Range (ATR) | 0.25 | 1.25 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 27.01 | 73.52 |
Price Performance
Historical ComparisonAbout ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.